Current Osteoporosis Reports

, Volume 10, Issue 1, pp 86–92

Nitric Oxide Donors for the Treatment of Osteoporosis

Future Therapeutics (P Miller, Section Editor)


The number of osteoporotic fractures is increasing worldwide as populations age. An inexpensive and widely available treatment is necessary to alleviate this increase in fractures. Current treatments decrease fractures at trabecular bone sites (spine) but have limited effects at cortical sites (hip, legs, forearm, and upper arm)—the most common sites of osteoporotic fracture. Treatments are also limited by costs, side effects, and lack of availability. Nitric oxide is a novel agent that has the potential to influence cortical bone, is inexpensive, is widely available, and has limited side effects. In this review we evaluate the in vitro and in vivo data which support the concept that nitric oxide is important in bone cell function, review the observational and case–control studies reporting on subjects taking organic nitrates that act as nitric oxide donors, and review the effects of nitrates on bone mineral density measurements and fracture risk.


Nitric oxide Osteoporosis Fracture Treatment 


Papers of particular interest, published recently, have been highlighted as:•• Of major importance

  1. 1.
    Cummings SR, Kelsey JL, Nevitt MC, O’Dowd KJ. Epidemiology of osteoporosis and osteoporotic fracture. Epidemiol Rev. 1985;7:178–208.PubMedGoogle Scholar
  2. 2.
    Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006;17(12):1726–33.PubMedCrossRefGoogle Scholar
  3. 3.
    Melton LJI, Cooper C. Magnitude and impact of osteoporosis and fractures. In: Marcus R, Feldman D, Kelsey J, editors. Osteoporosis. 2nd ed. San Diego: Academic; 2001. p. 557–67.CrossRefGoogle Scholar
  4. 4.
    Gullberg B, Johnell O, Kanis JA. World-wide projections for hip fracture. Osteoporos Int. 1997;7(5):407–13.PubMedCrossRefGoogle Scholar
  5. 5.
    Cummings SR. A 55-year-old woman with osteopenia. Jama. 2006;296(21):2601–10.PubMedCrossRefGoogle Scholar
  6. 6.
    Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348:1535–41.PubMedCrossRefGoogle Scholar
  7. 7.
    Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. Jama. 1998;280(24):2077–82.PubMedCrossRefGoogle Scholar
  8. 8.
    Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. Jama. 1999;282(14):1344–52.PubMedCrossRefGoogle Scholar
  9. 9.
    Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809–22.PubMedCrossRefGoogle Scholar
  10. 10.
    Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756–65.PubMedCrossRefGoogle Scholar
  11. 11.
    Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Jama. 1999;282(7):637–45.PubMedCrossRefGoogle Scholar
  12. 12.
    Neer RM, Arnaud CD, Zanchetta JR. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434–41.PubMedCrossRefGoogle Scholar
  13. 13.
    Cummings SR, Palermo L, Browner W, Marcus R, Wallace R, Pearson J, et al. Monitoring osteoporosis therapy with bone densitometry:misleading changes and regression to the mean. Fracture Intervention Trial Research Group. JAMA. 2000;8:1318–21.CrossRefGoogle Scholar
  14. 14.
    Cryer R, Bauer DC. Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence? Mayo Clin Proc. 2002;77(10):1031–43.PubMedCrossRefGoogle Scholar
  15. 15.
    Bauer DC, Black D, Ensrud K, Thompson D, Hochberg M, Nevitt M, et al. Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial. Arch Intern Med. 2000;160(4):517–25.PubMedCrossRefGoogle Scholar
  16. 16.
    Jamal SA, Bauer DC, Ensrud KE, Cauley JA, Hochberg M, Ishani A, et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J Bone Miner Res. 2007;22(4):503–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 25(11):2267–94.Google Scholar
  18. 18.
    Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. Jama. 2002;288(3):321–33.Google Scholar
  19. 19.
    Cummings SR, Cosman F, Jamal SA, eds. Osteoporosis. An evidenced-based guide to prevention and management. Philadelphia: American College of Physicians 2002.Google Scholar
  20. 20.
    Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. Jama. 1999;281(23):2189–97.PubMedCrossRefGoogle Scholar
  21. 21.
    Evans DM, Ralston SH. Nitric oxide and bone. J Bone Miner Res. 1996;11(3):300–5.PubMedCrossRefGoogle Scholar
  22. 22.
    Chae HJ, Park RK, Chung HT, Kang JS, Kim MS, Choi DY, et al. Nitric oxide is a regulator of bone remodelling. J Pharm Pharmacol. 1997;49(9):897–902.PubMedCrossRefGoogle Scholar
  23. 23.
    Evans CH, Stefanovic-Racic M, Lancaster J. Nitric oxide and its role in orthopaedic disease. Clin Orthop. 1995;312:275–94.PubMedGoogle Scholar
  24. 24.
    Feelisch M. Biotransformation to nitric oxide of organic nitrates in comparison to other nitrovasodilators. Eur Hear J. 1993;14:123–32.Google Scholar
  25. 25.
    Brandi ML, Hukkanen M, Umeda T, Moradi-Bidhendi N, Bianchi S, Gross SS, et al. Bidirectional regulation of osteoclast function by nitric oxide synthase isoforms. Proceedings of the National Academy of Sciences USA. 1995;92:2954–8.CrossRefGoogle Scholar
  26. 26.
    Collin-Osdoby P, Nickols GA, Osdoby P. Bone cell function, regulation and communication: a role for nitric oxide. J Cell Biochem. 1995;57:399–408.PubMedCrossRefGoogle Scholar
  27. 27.
    Kasten TP, Collin-Osdoby P, Patel N, Osdoby P, Krukowski M, Misko TP, et al. Potentiation of osteoclast bone-resorption activity by inhibition of nitric oxide synthase. Proc Natl Acad Sci U S A. 1994;91(9):3569–73.PubMedCrossRefGoogle Scholar
  28. 28.
    Lowik CW, Nibbering PH, van de Ruit M, Papapoulos SE. Inducible production of nitric oxide in osteoblast-like cells and in fetal mouse bone explants is associated with suppression of osteoclastic bone resorption. J Clin Invest. 1994;93(4):1465–72.PubMedCrossRefGoogle Scholar
  29. 29.
    MacIntyre I, Zaidi M, Alam AS, Datta HK, Moonga BS, Lidbury PS, et al. Osteoclastic inhibition: an action of nitric oxide not mediated by cyclic GMP. Proc Natl Acad Sci U S A. 1991;88(7):2936–40.PubMedCrossRefGoogle Scholar
  30. 30.
    Ralston SH. Osteoporosis. BMJ. 1997;315(7106):469–72.PubMedCrossRefGoogle Scholar
  31. 31.
    Ralston SH, Ho LP, Helfrich MH, Grabowski PS, Johnston PW, Benjamin N. Nitric oxide: a cytokine-induced regulator of bone resorption. J Bone Miner Res. 1995;10(7):1040–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Collin-Osdoby P, Li L, Rothe L, Anderson F, Kirsch D, Oursler MJ, et al. Inhibition of avian osteoclast bone resorption by monoclonal antibody 121 F: a mechanism involving the osteoclast free radical system. J Bone Miner Res. 1998;13(1):67–78.PubMedCrossRefGoogle Scholar
  33. 33.
    Ralston SH. The Michael Mason Prize Essay 1997. Nitric oxide and bone: what a gas! Br J Rheumatol. 1997;36(8):831–8.PubMedCrossRefGoogle Scholar
  34. 34.
    Chow JW, Fox SW, Lean JM, Chambers TJ. Role of nitric oxide and prostaglandins in mechanically induced bone formation. J Bone Miner Res. 1998;13(6):1039–44.PubMedCrossRefGoogle Scholar
  35. 35.
    Ake Y, Saegusa Y, Matsubara T, Mizuno K. Cultured osteoblast synthesize nitric oxide in response to cytokines and lipopolysaccharide. Kobe J Med Sci. 1994;40(3–4):125–37.PubMedGoogle Scholar
  36. 36.
    Aguirre J, Buttery L, O’Shaughnessy M, Afzal F, Fernandez de Marticorena I, Hukkanen M, et al. Endothelial nitric oxide synthase gene-deficient mice demonstrate marked retardation in postnatal bone formation, reduced bone volume, and defects in osteoblast maturation and activity. Am J Pathol. 2001;158(1):247–57.PubMedCrossRefGoogle Scholar
  37. 37.
    Armour KE, Armour KJ, Gallagher ME, Godecke A, Helfrich MH, Reid DM, et al. Defective bone formation and anabolic response to exogenous estrogen in mice with targeted disruption of endothelial nitric oxide synthase. Endocrinology. 2001;142(2):760–6.PubMedCrossRefGoogle Scholar
  38. 38.
    Wimalawansa SJ, De Marco G, Gangula P, Yallampalli C. Nitric oxide donor alleviates ovariectomy-induced bone loss. Bone. 1996;18(4):301–4.PubMedCrossRefGoogle Scholar
  39. 39.
    Jamal SA, Browner WS, Bauer DC, Cummings SR. Intermittent use of nitrates increases bone mineral density: the study of osteoporotic fractures. J Bone Miner Res. 1998;13(11):1755–9.PubMedCrossRefGoogle Scholar
  40. 40.
    Abshagen A, Sporl-Radun S. First data on effects and pharmacokinetics of isosorbide-5-mononitrate in normal man. Eur J Clin Pharmacol. 1981;19:423–9.PubMedCrossRefGoogle Scholar
  41. 41.
    Wimalawansa SJ, Chapa T, Wimalawansa S, Fang L, Yallampalli C. Dose and frequency effects of nitric oxide donor nitroglycerine on bone. Seventy- ninth Annual Meeting of the Endocrine Society, Minneapolis, USA. 1997:(abst P3-248).Google Scholar
  42. 42.
    Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med. 1995;332(12):767–73.PubMedCrossRefGoogle Scholar
  43. 43.
    Pouwels S, Lalmohamed A, van Staa T, Cooper C, Souverein P, Leufkens HG, et al. Use of organic nitrates and the risk of hip fracture: a population-based case–control study. J Clin Endocrinol Metab. 95(4):1924–31.Google Scholar
  44. 44.
    Rejnmark L, Vestergaard P, Mosekilde L. Decreased fracture risk in users of organic nitrates: a nationwide case–control study. J Bone Miner Res. 2006;21(11):1811–7.PubMedCrossRefGoogle Scholar
  45. 45.
    •• Jamal SA, Cummings SR, Hawker GA. The effects of isosorbide mononitrate on bone turnover: A randomized controlled trial. J Bone Miner Res. 2004;19(9):1512–7. This is a randomized trial that reported on the effects of the NO donor ISMO on bone turnover markers in healthy women.PubMedCrossRefGoogle Scholar
  46. 46.
    Fung H. Pharmacokinetics of nitroglycerin and long-acting nitrate esters. Am J Med. 1983;12:13–20.CrossRefGoogle Scholar
  47. 47.
    Thadani U. Nitrate tolerance, rebound, and their clinical relevance in stable angina pectoris, unstable angina, and heart failure. Cardiovascular Drugs and Therapy. 1997;10:734–42.CrossRefGoogle Scholar
  48. 48.
    Clowes JA, Eastell R. Markers of bone turnover and laboratory evaluation of secondary osteoporosis. In: Cummings SR, Cosman F, Jamal SA, editors. Osteoporosis: an evidenced-based guide to prevention and management. Philadelphia: American College of Physicians; 2002. p. 59–82.Google Scholar
  49. 49.
    Looker AC, Bauer DC, Chesnut 3rd CH, Gundberg CM, Hochberg MC, Klee G, et al. Clinical use of biochemical markers of bone remodeling: current status and future directions. Osteoporos Int. 2000;11(6):467–80.PubMedCrossRefGoogle Scholar
  50. 50.
    Wimalawansa SJ. Nitroglycerin therapy is as efficacious as standard estrogen replacement therapy (Premarin) in prevention of oophorectomy-induced bone loss: a human pilot clinical study. J Bone Miner Res. 2000;15(11):2240–4.PubMedCrossRefGoogle Scholar
  51. 51.
    •• Jamal SA, Hamilton CJ, Eastell R, Cummings SR. Effect of nitroglycerin ointment on bone density and strength in postmenopausal women: a randomized trial. Jama. 305(8):800–7. This is a randomized trial that reported on the effects on the NO donor nitroglycerin on BMD, bone geometry, and bone turnover markers. Google Scholar
  52. 52.
    Burghardt AJ, Kazakia GJ, Sode M, de Papp AE, Link TM, Majumdar S. A longitudinal HR-pQCT study of alendronate treatment in post-menopausal women with low bone density: Relations between density, cortical and trabecular micro-architecture, biomechanics, and bone turnover. J Bone Miner Res. 2010;25(12):2267–528.CrossRefGoogle Scholar
  53. 53.
    Macdonald HM, Nishiyama KK, Hanley DA, Boyd SK. Changes in trabecular and cortical bone microarchitecture at peripheral sites associated with 18 months of teriparatide therapy in postmenopausal women with osteoporosis. Osteoporos Int. May 11.Google Scholar
  54. 54.
    Seeman E, Delmas PD, Hanley DA, Sellmeyer D, Cheung AM, Shane E, et al. Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res. 25(8):1886–94.Google Scholar
  55. 55.
    Ahlborg HG, Johnell O, Turner CH, Rannevik G, Karlsson MK. Bone loss and bone size after menopause. N Engl J Med. 2003;349(4):327–34.PubMedCrossRefGoogle Scholar
  56. 56.
    Black DM, Bouxsein ML, Marshall LM, Cummings SR, Lang TF, Cauley JA, et al. Proximal femoral structure and the prediction of hip fracture in men: a large prospective study using QCT. J Bone Miner Res. 2008;23(8):1326–33.PubMedCrossRefGoogle Scholar
  57. 57.
    Wimalawansa SJ, Grimes JP, Wilson AC, Hoover DR. Transdermal nitroglycerin therapy may not prevent early postmenopausal bone loss. J Clin Endocrinol Metab. 2009;94(9):3356–64.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Multidisciplinary Osteoporosis Research ProgramWomen’s College HospitalTorontoCanada
  2. 2.Department of MedicineUniversity of TorontoTorontoCanada
  3. 3.Department of Exercise SciencesUniversity of TorontoTorontoCanada

Personalised recommendations